CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review

被引：38

作者：

Urits, Ivan

Jones, Mark R.

Gress, Kyle

Charipova, Karina

Fiocchi, Jacob

Kaye, Alan D.

Viswanath, Omar

机构：

[1] Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, 330 Brookline Ave, Boston, 02215, MA

[2] Georgetown University School of Medicine, Washington, DC

[3] Creighton University School of Medicine-Phoenix Regional Campus, Phoenix, AZ

[4] Department of Anesthesiology, Louisiana State University Health Sciences Center, New Orleans, LA

[5] Valley Anesthesiology and Pain Consultants, Phoenix, AZ

[6] University of Arizona College of Medicine-Phoenix, Phoenix, AZ

[7] Creighton University School of Medicine, Omaha, NE

来源：

CURRENT PAIN AND HEADACHE REPORTS | 2019年 / 23卷 / 05期

关键词：

Chronic migraines; Episodic migraines; Calcitonin gene receptor peptide (CGRP) antagonist; Erenumab; GENE-RELATED PEPTIDE; ACTIVITY-MODIFYING PROTEIN-1; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; TRIGEMINOVASCULAR SYSTEM; PREVENTIVE TREATMENT; RECEPTOR; ERENUMAB; SAFETY; LBR-101;

D O I：

10.1007/s11916-019-0768-y

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Purpose of ReviewThe purpose of the following review is to summarize the most recent understanding of migraine pathophysiology, as well as of basic and clinical science pharmacologic literature regarding the development of calcitonin gene receptor peptide (CGRP) antagonists as a novel therapeutic modality for the treatment of migraine headaches. A review is provided of erenumab, the first of its class FDA approved CGRP antagonist.Recent FindingsDespite its high prevalence, the occurrence and treatment of migraine headaches is poorly understood. Erenumab and CGRP antagonists as a whole significantly reduce the average number of migraine days experienced in migraine sufferers.SummaryCGRP antagonists appear to significantly improve treatment outcomes in patients who suffer from episodic and chronic migraines. Erenumab is the first CGRP antagonist to be FDA approved for public use; however, further development of biologics in this class is underway.

引用

页数：10

共 63 条

[1]

[Anonymous], 1988, NEUROSCIENCE, DOI DOI 10.1016/0306-4522(88)90018-8

[2] Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development [J].

Archbold, Julia K. ;

Flanagan, Jack U. ;

Watkins, Harriet A. ;

Gingell, Joseph J. ;

Hay, Debbie L. .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2011, 32 (10) :591-600

[3]

Bajwa ZH, 2018, EVALUATION HEADACHE

[4]

Bajwa ZH, 2018, CUTE TREATMENT MIGRA

[5]

Bajwa ZH, 2018, PREVENTIVE TREATMENT

[6] Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP [J].

Bigal, Marcelo E. ;

Walter, Sarah ;

Bronson, Michele ;

Alibhoy, Abbas ;

Escandon, Rafael .

CEPHALALGIA, 2014, 34 (12) :968-976

[7] Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program [J].

Bigal, Marcelo E. ;

Escandon, Rafael ;

Bronson, Michele ;

Walter, Sarah ;

Sudworth, Maria ;

Huggins, John P. ;

Garzone, Pamela .

CEPHALALGIA, 2014, 34 (07) :483-492

[8] SOLUTION STRUCTURE OF HUMAN CALCITONIN GENE-RELATED PEPTIDE BY H-1-NMR AND DISTANCE GEOMETRY WITH RESTRAINED MOLECULAR-DYNAMICS [J].

BREEZE, AL ;

HARVEY, TS ;

BAZZO, R ;

CAMPBELL, ID .

BIOCHEMISTRY, 1991, 30 (02) :575-582

[9] Elevated Saliva Calcitonin Gene-Related Peptide Levels During Acute Migraine Predict Therapeutic Response to Rizatriptan [J].

Cady, Roger K. ;

Vause, Carrie V. ;

Ho, Tony W. ;

Bigal, Marcelo E. ;

Durham, Paul L. .

HEADACHE, 2009, 49 (09) :1258-1266

[10]

CHOY M, 2018, P & T, V43, P462

← 1 2 3 4 5 6 7 →